奥拉帕利辅助治疗gBRCA突变高危HER2阴性早期乳腺癌的持续获益:OlympiA III期试验更新结果
OlympiA III期试验随机比较1年辅助奥拉帕利与安慰剂,用于1836例gBRCA致病性变异、高危HER2阴性早期乳腺癌患者。中位随访6.1年的第三次预设分析显示,奥拉帕利在IDFS、DDFS和OS上获益持续,6年OS为87.5%对83.2%,安全性可接受且MDS/AML风险未增加。
要点
- 辅助奥拉帕利维持IDFS获益(HR 0.65,95%CI 0.53-0.78)
- 6年OS奥拉帕利87.5%对安慰剂83.2%,差4.4%
- AESI风险未增加(6.3%对9.3%),MDS/AML未增加
核心结论
- 在中位随访6.1年时,1年辅助奥拉帕利在gBRCA致病性变异、高危HER2阴性早期乳腺癌中持续改善IDFS、DDFS和OS,毒性可接受且未增加MDS/AML风险。
研究设计与样本
- 随机III期OlympiA试验(NCT02032823)纳入1836例gBRCA1/2致病性或可能致病性变异、高危HER2阴性早期乳腺癌患者,比较1年辅助奥拉帕利与安慰剂。
- 本次为第三次预设 interim analysis,中位随访6.1年,描述性分析主要终点IDFS及关键次要终点DDFS和OS。
主要发现
- 奥拉帕利维持IDFS获益(HR 0.65,95%CI 0.53-0.78)、DDFS获益(HR 0.65,95%CI 0.53-0.81)和OS获益(HR 0.72,95%CI 0.56-0.93)。
- 6年OS奥拉帕利组87.5%对安慰剂组83.2%,差异4.4%(95%CI 0.9%-6.7%)。
- 奥拉帕利获益在所有关键亚组中一致,包括高危激素受体阳性疾病患者。
- 奥拉帕利组BRCA相关新发乳腺癌和卵巢/输卵管癌病例更少。
- AESI发生率奥拉帕利组6.3%对安慰剂组9.3%,MDS/AML为0.4%对0.7%。
关键数值与推荐
- IDFS:HR 0.65(95%CI 0.53-0.78)。
- DDFS:HR 0.65(95%CI 0.53-0.81)。
- OS:HR 0.72(95%CI 0.56-0.93);6年OS 87.5%对83.2%,差异4.4%(95%CI 0.9%-6.7%)。
- AESI:6.3%对9.3%;MDS/AML:0.4%对0.7%。
临床怎么用
- gBRCA致病性变异、高危HER2阴性早期乳腺癌患者在(新)辅助化疗后,可考虑1年辅助奥拉帕利治疗以持续改善IDFS、DDFS和OS。
- 治疗期间需关注AESI,但现有数据未显示MDS/AML风险增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The randomised phase III OlympiA trial (NCT02032823) compared 1 year of adjuvant olaparib [oral poly (ADP-ribose) polymerase inhibitor] with placebo in 1836 patients with pathogenic/likely pathogenic BRCA1 or BRCA2 [germline BRCA pathogenic variants (gBRCApvs)] germline variants and high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (BC). Previous interim analyses (IAs) demonstrated statistically significant improvements in invasive disease-free survival (IDFS), distant disease-free survival (DDFS) and overall survival (OS), irrespective of hormone receptor status, prior platinum administration, timing of prior chemotherapy or type of gBRCApv. Herein are the results of the third prespecified IA with a median follow-up (MFU) of 6.1 years. PATIENTS AND METHODS: Descriptive analyses are presented for the primary endpoint IDFS and key secondary endpoints of DDFS and OS. Estimates of the hazard ratio (HR) based on the stratified Cox's proportional hazards model and 95% confidence intervals (CIs) are presented with yearly event rates at an MFU of ≤6.1 years. Safety analyses included adverse events of special interest (AESIs). RESULTS: Olaparib benefits were maintained in IDFS (HR 0.65, 95% CI 0.53-0.78), DDFS (HR 0.65, 95% CI 0.53-0.81) and OS (HR 0.72, 95% CI 0.56-0.93). The 6-year OS for olaparib versus placebo was 87.5% versus 83.2% (difference 4.4%, 95% CI 0.9% to 6.7%). Olaparib benefit was consistent across all key subgroups, including patients with high-risk hormone receptor-positive disease. There were fewer BRCA-associated new BC and ovarian/fallopian tube cancer cases and there was no increase in AESI risks (6.3% versus 9.3%), including myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) (0.4% versus 0.7%), with olaparib versus placebo. CONCLUSIONS: At an MFU of 6.1 years, 1 year of adjuvant olaparib after (neo)adjuvant chemotherapy demonstrated ongoing clinically meaningful improvements in IDFS, DDFS and OS in patients with gBRCApvs and high-risk, HER2-negative early BC, with acceptable toxicity and without increased risk of MDS/AML. These data continue to provide support for adjuvant olaparib in the treatment of gBRCApv-associated high-risk, HER2-negative early BC.
引用
- Garber JE, Cameron D, Campbell C, et al. Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial. Ann Oncol. 2026. PMID: 42636977. doi:10.1016/j.annonc.2026.08.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。